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SUMMARY
We conducted a mutational analysis of residues potentially involved in the adenine nucleotide
binding pocket of the human P2Y1 receptor. Mutated receptors were expressed in COS-7 cells
with an epitope tag that permitted confirmation of expression in the plasma membrane, and
agonist-promoted inositol phosphate accumulation was assessed as a measure of receptor activity.
Residues in transmembrane helical domains (TMs) 3, 5, 6, and 7 predicted by molecular modeling
to be involved in ligand recognition were replaced with alanine and, in some cases, by other amino
acids. The potent P2Y1 receptor agonist 2-methylthio-ATP (2-MeSATP) had no activity in cells
expressing the R128A, R310A, and S314A mutant receptors, and a markedly reduced potency of
2-MeSATP was observed with the K280A and Q307A mutants. These results suggest that residues
on the exofacial side of TM3 and TM7 are critical determinants of the ATP binding pocket. In
contrast, there was no change in the potency or maximal effect of 2-MeSATP with the S317A
mutant receptor. Alanine replacement of F131, H132, Y136, F226, or H277 resulted in mutant
receptors that exhibited a 7–18-fold reduction in potency compared with that observed with the
wild-type receptor. These residues thus seem to subserve a less important modulatory role in
ligand binding to the P2Y1 receptor. Because changes in the potency of 2-methylthio-ADP and 2-
(hexylthio)-AMP paralleled the changes in potency of 2-MeSATP at these mutant receptors, the β-
and γ-phosphates of the adenine nucleotides seem to be less important than the α-phosphate in
ligand/P2Y1 receptor interactions. However, T221A and T222A mutant receptors exhibited much
larger reductions in triphosphate (89- and 33-fold versus wild-type receptors, respectively) than in
diphosphate or monophosphate potency. This result may be indicative of a greater role of these
TM5 residues in γ-phosphate recognition. Taken together, the results suggest that the adenosine
and α-phosphate moieties of ATP bind to critical residues in TM3 and TM7 on the exofacial side
of the human P2Y1 receptor.
Extracellular ATP acts via membrane-bound receptors as a neurotransmitter in the central
and peripheral nervous systems and as a regulator of vascular and smooth muscle tone (1).
Two pharmacologically distinct families of ATP receptors, the P2X receptor class of ligand-
gated ion channels and the P2Y receptor class of GPCRs, have been described (2, 3). As
many as seven subtypes have been cloned within each family.1
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P2Y receptors are members of the superfamily of rhodopsin-like GPCRs. Many other
members of this superfamily, including adenosine receptors, have been probed using site-
directed mutagenesis (4–10). Among P2Y receptors, only the P2Y2 receptor (11), which
binds both purine and pyrimidine nucleotides, has been studied using mutagenesis. The
P2Y1 receptor subtype is a phospholipase C-activating ATP receptor present in heart,
skeletal muscle, and various smooth muscles. Both P2Y1 (12) and P2Y2 (11, 13) receptors
have been modeled using rhodopsin (14–16)2 or bacteriorhodopsin (17), respectively, as a
template. There are substantial pharmacological differences between these two subtypes,
and the overall percent identity of amino acids in the human sequences is only 38%.
In this study, we attempted to characterize the determinants of ligand recognition in the
family of P2Y receptors by site-directed mutagenesis. Activation of phospholipase C by
three nucleotide ligands was used as an indicator of receptor function. We explored the role
of positively charged and conserved residues in TM3, TM6, and TM7 and found that
residues3 R128(3.29), R310(7.39), and S314(7.43) are critical for the binding of nucleotides
to human P2Y1 receptors.
A long-range goal of this investigation is the design of more selective pharmacological
agents based on structural differences in receptors. A limitation in the study of P2 receptors
is the lack of high affinity antagonist radioligands. Although no specific, high affinity
agonists or antagonists are available for the cloned subtypes, we previously introduced
agonist probes that reveal pharmacological heterogeneity within the two superfamilies (18–
20). One such agonist used in this study is HT-AMP (20), which activates P2Y1 but not
P2Y2 receptors with a potency greater than that of the endogenous agonist ATP. The
availability of a potent AMP derivative allowed us to compare various agonists to probe the
phosphate binding region of the receptor.
Experimental Procedures
Materials
The human P2Y1 receptor cDNA (pcDNA3P2Y1) was prepared as previously described
(21). KlenTaq polymerase for the PCR was purchased from Clontech (Palo Alto, CA). All
endonuclease restriction enzymes used in this study were obtained from New England
Biolabs (Beverly, MA). The agonists 2-MeSATP and 2-Me-SADP were from RBI (Natick,
MA). The agonist HT-AMP was synthesized as previously described (18, 20) as the
ammonium salt, which was more soluble in aqueous medium than the triethylammonium
salt. The antagonists suramin and PPADS were from Tocris Cookson (St. Louis, MO).
Reactive Blue 2 was from Aldrich (Milwaukee, WI). myo-[3H]inositol (15 Ci/mmol) was
obtained from American Radiolabeled Chemicals (St. Louis, MO). FBS and o-
phenylenediamine dihydrochloride were purchased from Sigma Chemical (St. Louis, MO).
The Sequenase Kit, ATP, and cAMP were from United States Biochemical (Cleveland,
OH). All oligonucleotides were synthesized by Bioserve Biotechnologies (Laurel, MD). A
monoclonal antibody (12CA5) against an HA epitope was purchased from Boehringer-
Mannheim Biochemicals (Indianapolis, IN), and goat anti-mouse IgG (γ-chain specific)
1P2Y1–P2Y7 sequences have been cloned and named in the literature (3), however, several of these may be either receptors of a
different family (e.g.,P2Y5 and possibly P2Y7) or possibly species homologues (e.g., P2Y3 and P2Y6). The identity and relationship
among these clones require further study.
2The coordinates of the P2Y1 receptor model are available from the protein database (Brookhaven National Laboratory) using the
URL http://www.pdb.bnl.gov/cgi-bin/browse under the ID code 1ddd.
3Residue identifiers as described in van Rhee and Jacobson (4) specify the helix (X) and the position relative to a key conserved
residue in that helix, which is designated (X0.50). For example, for the helices mutated in the present study, the key conserved
residues are R149(3.50), P229(5.50), P275(6.50), and P321(7.50).
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antibody conjugated with horseradish peroxidase was purchased from Sigma. DEAE-
dextran was obtained from Pharmacia-LKB (Piscataway, NJ).
Plasmid construction and site-directed mutagenesis
The coding region of pCDNA3P2Y1 was subcloned into the pCD-PS expression vector (22),
yielding pCDP2Y1. All mutations were introduced into pCDP2Y1 using standard PCR
mutagenesis techniques (23). The accuracy of all PCR-derived sequences was confirmed by
dideoxy sequencing of the mutant plasmids (24).
Epitope tagging
A 9-amino acid sequence derived from the influenza virus HA protein (TAC CCA TAC
GAC GTG CCA GAC TAC GCG; peptide sequence, YPYDVPDYA) was inserted after the
M residue at the extracellular amino terminus of the human P2Y1 ATP receptor gene (21).
Oligonucleotides containing the HA-tag sequence were designed and used to generate a
PCR fragment, which was then used to replace the corresponding wild-type P2Y1 sequence.
A HexaHis tag (25) was also included at the carboxyl terminus immediately after the L
residue, resulting in a construct suitable for potential affinity chromatography using a nickel
column.
Transient expression of mutant receptors in COS-7 cells
COS-7 cells (2 × 106) were seeded onto 100-mm culture dishes containing 10 ml of DMEM
supplemented with 10% FBS. Cells were transfected ~24 hr later with plasmid DNA (4 μg
of DNA/dish) according to the DEAE-dextran method (26) and grown for an additional 72
hr at 37°.
Inositol phosphate determination
COS-7 cells were subcultured into 12 × 100-mm dishes (Falcon) at a density of ~1 × 106
cells/dish. After overnight incubation at 37° and 5% CO2, the cells were transfected with
plasmids containing receptor-coding sequence using the DEAE-Dextran method for 40 min,
followed by treatment with 100 μM chloroquine for 2.5 hr. Typically, two dishes of COS-7
cells were transfected for each mutant tested.
The assay was carried out according to the general approach of Harden et al. (27). At ~24 hr
after transfection, the cells were split into six-well plates (~0.75 × 106 cells/well; Costar,
Cambridge, MA) in DMEM culture medium (plus 100 units/ml of penicillin, 100 μg/ml
streptomycin, 2 μmol/ml glutamate, and 10% fetal calf serum) supplemented with 3 μCi/ml
of myo-[3H]inositol. After a 24-hr labeling period, cells were preincubated for 30 min at 37°
with 10 mM LiCl. The mixtures were swirled to ensure uniformity before they were allowed
to stand for 20 min at room temperature. 2-MeSATP was added, and the cells were
incubated for 30 min at 37° and 5% CO2. The supernatant was removed by aspiration, and
750 μl of cold 20 mM formic acid was added to each well. Cell extracts were collected after a
30-min incubation at 4° and neutralized with 250 μl of 60 mM NH4OH. The inositol
monophosphate fraction was then isolated by anion exchange chromatography (28). The
contents of each well was applied to a small anion exchange column (AG-1-X8; BioRad,
Hercules, CA) that had been pretreated with 15 ml of 0.1 M formic acid/3 M ammonium
formate, followed by 15 ml of water. The columns were then washed with 15 ml of a
solution containing 5 mM sodium borate and 60 mM sodium formate. [3H]Inositol phosphates
were eluted with 4.5 ml of 0.1 M formic acid/0.2 M ammonium formate and quantified by
liquid scintillation counting (LKB Wallace 1215 Rack-beta scintillation counter).
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Pharmacological parameters were analyzed using KaleidaGraph (version 3.01; Abelbeck/
Synergy Software, Reading, PA). Statistical analysis was performed using the Alternate t
test (InStat version 2.04; GraphPAD, San Diego, CA).
ELISA
For indirect cellular ELISA measurements, cells were transferred to 96-well dishes (4–5 ×
104 cells/well) at 1 day after transfection. At ~72 hr after transfection, cells were fixed in 4%
formaldehyde in PBS for 30 min at room temperature. After washing three times with PBS
and blocking with DMEM (containing 10% FBS), cells were incubated with HA specific
monoclonal antibody (12CA5; 20 μg/ml) for 3 hr at 37°. Plates were washed and incubated
with a 1:2000 dilution of a peroxidase-conjugated goat anti-mouse IgG antibody (Sigma) for
1 hr at 37°. Hydrogen peroxide and ophenylenediamine (each 2.5 mM in 0.1 M phosphate-
citrate buffer, pH 5.0) served as substrate and chromogen, respectively. The enzymatic
reaction was stopped after 30 min at room temperature with 1 M H2SO4 solution containing
0.05 M Na2SO3, and the color development was measured bichromatically with a
BioKinetics reader (EL 312; Bio Tek Instruments, Winooski, VT) at 490 and 630 nm
(baseline).
Results
Sequence alignments for selected transmembrane regions of P2Y receptors and other G
protein-coupled receptors are shown in Fig. 1. The residues of the human P2Y1 receptor
selected as targets for site-directed mutagenesis are shown in bold; they include the
positively charged residues R128, K280, and R310 in TM3, TM6, and TM7, respectively,
which also appear in some but not all of the other P2Y sequences. K280 and R310 were
suggested in our modeling study of the chick P2Y1 receptor (12)2 to be involved in the
binding of the phosphate moiety of nucleotides. Mutated residues also include F226 and
S317, which are highly conserved among GPCRs. Another mutated residue, H277, is
conserved among six of the seven known P2Y receptor sequences and among three of the
four adenosine receptor sequences. Other mutated residues include H132, T221, and Q307,
which are unique to P2Y1 receptors within the P2Y class of GPCRs. In addition, other
uncharged residues targeted for mutagenesis that have been predicted through molecular
modeling to be in proximity to the ligand binding site are: F131 and Y136 in TM3, T222 in
TM5, and Q307 and S314 in TM7. Each of these amino acid residues was individually
replaced with alanine and/or other amino acids (see below). In addition, each mutant
contained an epitope-tag sequence included at the amino terminus for immunological
detection (see below) and a hexa-His tag at the carboxyl terminus, potentially for future
purification using Ni-affinity chromatography (25). The pharmacological properties were
compared with those of the wild-type receptor that was similarly modified.
ELISA assay for receptors located at the cell surface
Mutant P2Y1 receptors were detected immunologically at the plasma membrane surface by
virtue of the HA-tag and the 12CA5 monoclonal antibody. This assay is specific for receptor
proteins in which the amino-terminal sequence is accessible to the extracellular medium
(i.e., of the proper orientation in the plasma membrane). This ELISA procedure does not
interfere with the intactness of the plasma membrane barrier (5). To estimate approximate
levels of receptor protein present in the plasma membrane, a standard curve was constructed
from different batches of transfected COS-7 cells expressing different levels of HA-tagged
P2Y1 wild-type receptors (see Experimental Procedures; Ref. 5).
Table 1 shows that the mutant receptors were expressed on the cell surface using ELISA (5).
Expression levels for the various mutants (HA-tagged wild-type receptor = 100%)
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determined by this method (eight experiments) ranged from 50% to 260% (Table 1). The
combination of ELISA and the functional assays discussed below indicates which residues
are important, either directly for activation of the receptor or indirectly for the high affinity
binding of agonists.
Functional assay
Agonist-promoted production of inositol phosphates was measured to determine whether
mutant receptors were functionally active (Table 2). COS-7 cells transiently expressing
wild-type human P2Y1 receptors displayed a substantial increase of inositol phosphates in
response to the potent agonist 2-MeSATP (EC50 = 6.75 nM), which was not observed in
control cells (Fig. 2). At the highest concentration of the agonist tested (1 mM), there was a
slight increase of inositol phosphates in control COS-7 cells, presumably from an
endogenous nucleotide receptor. The difference in basal inositol phosphate levels of the
various expressed receptors occurs due to release of endogenous ATP and concomitant
differential activation of receptors that are sensitive to activation by low concentrations of
nucleotide versus mutant receptors that are only activated by higher concentrations of
nucleotide. The broad concentration-effect curves reflect both the noise introduced by a
limited number of data points and the fact that the assays were for a length of time (30 min)
during which agonist-induced desensitization of the inositol lipid signaling response
occurred.
The most critical residues for activation of phospholipase C by 2-MeSATP were found in
TM3, TM6, and TM7 (Fig. 3). The ability of the agonist 2-MeSATP to stimulate production
of inositol phosphates at the R128A, R310A, and S314A mutant receptors was virtually
abolished because at 1 mM 2-Me-SATP, <20% of the stimulation found in mutant receptors
was observed. The ligand recognition properties of the S314A mutant could be rescued
substantially by substitution with T instead of A (Fig. 2B). Thus, the potency of 2-MeSATP
at S314T mutant receptors was only 8.9-fold reduced compared with wild-type receptors.
The effect of substituting R310 with another positively charged residue, K, was tested. The
resulting R310K mutant receptor remained poorly responsive to agonist, with 2-MeSATP
680-fold less potent than at wild-type receptors. An attempt to rescue the activity in an R310
mutant with the double revertant mutant R310S/S314R resulted in a nonfunctional receptor
(Fig. 2B).
The K280A and Q307A mutant receptors displayed greatly diminished potency with 2-
MeSATP (950- and 210-fold less, respectively) compared with wild-type receptors,
although the receptors were well expressed (Table 1). In contrast, replacement of other
amino acids, located in TMs 3, 5, 6, and 7 (but more distal from the exofacial side than the
above critical residues as shown in Fig. 3) did not have as pronounced an effect on agonist
activation of phospholipase C (Table 2). The maximal effect and potency of 2-MeSATP at
the S317A mutant receptor were identical to those observed with the native receptor.
Moreover, basal activity was unchanged from wild-type receptors, whereas other mutant
receptors showed lower basal activity levels. Alanine substitution at residues F131, H132,
Y136, T221, T222, F226, and H277 resulted in intermediate potency of the agonist,
suggesting a modulatory and less critical role of those residues in ligand binding. The
potency of 2-MeSATP was reduced compared with wild-type receptors by 15–100-fold in
Y136, T221, T222, and H277 mutant receptors and by 3–15-fold in F131A, H132A, and
F226A mutant receptors.
The potencies of the agonists 2-MeSADP and HT-AMP were also measured in wild-type
and mutant receptors. HTAMP was selected as the monophosphate to be tested in this
comparison rather than 2-MeSAMP to allow precise determination of potency in the
functional assay. The extended chain at the 2-position enhanced potency over simple AMP
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analogues (20). As observed previously with the wild-type receptor (21) and with the P2Y1
receptor in turkey erythrocytes (18), the diphosphate analogue was more potent than the
triphosphate. Potency changes for the agonists 2-MeSADP and HT-AMP in general
paralleled changes in potency for 2-MeSATP (Table 2). The ratio for potency of
diphosphate versus triphosphate was generally 5–10-fold. An exception was the H277A
mutant receptor, where diphosphates and triphosphates were equipotent. The potency of 2-
MeSADP at most mutant receptors was generally 100–200-fold greater than for HT-AMP.
In the case of the S317A mutant receptor, the potency ratio for 2-MeSADP versus HT-AMP
was ~400.
These results suggest that receptor structure-function relationships are independent of
specific interactions of the βand γ-phosphates with the receptor. The residues that were
found most critical for activation by 2-MeSATP (R128, R310, and S314) were also
absolutely critical for activation of the receptor by monophosphates and diphosphates. In
addition, the K280A mutant receptor had greatly diminished potency of monophosphates
and diphosphates as well as the triphosphates. The one instance of an alanine mutation with
no effect on triphosphate potency (S317A) yielded identical results for monophosphates and
diphosphates. However, subtle differences were noted in the relative effects of a given
mutation on potency of monophosphates versus triphosphates. For example, the F131A
mutation was relatively more important in reducing the potency of HT-AMP (15-fold) than
of 2-MeSATP (6.5-fold). The potency shifts for agonists at other mutant receptors versus
wild-type receptors were less pronounced for HT-AMP versus 2-MeSATP: H132A (6.7-
versus 12-fold), Y136A (4.8- versus 18-fold), T221A (5.1- versus 89-fold), and T222A (3.4-
versus 33-fold). Among these cases of divergence between HT-AMP and 2-MeSATP, the
differences between the two agonists were the greatest at T221A and T222A mutant
receptors. The change in potencies of 2-Me-SADP at T221A and T222A mutant receptors
(13- and 8.8-fold, respectively) versus wild-type receptors were intermediate between those
for monophosphates and triphosphates. The consistency of this trend at T221A and T222A
mutant receptors suggests a greater contribution of the γ-phosphate moiety of ATP in ligand
recognition at this region of TM5.
The effects of ATP antagonists (29) at wild-type receptors and at six mutant receptors at
which 2-MeSATP was fully active (S317A, S314T, H277A, Q307A, K280A, and R310K)
were probed using the same functional assay (Fig. 4). The weak, nonselective antagonists
suramin, PPADS, and Reactive Blue 2, at concentrations of 100 μM, were tested in the
presence of a concentration of 2-MeSATP that caused ~50% stimulation of phospholipase C
in each case (Fig. 4A). Suramin and PPADS each partially (~20%) blocked the agonist
effects at this concentration; however, Reactive Blue 2 had no significant effect. Although
IC50 values were not determined, it seemed that both suramin and PPADS retained
antagonist properties at all of the mutant receptors examined (Fig. 4B).
Discussion
Stimulation of phospholipase C by mutant human P2Y1 receptors
A mutational analysis of residues potentially involved in the adenine nucleotide binding
pocket of the human P2Y1 receptor has been carried out. Single amino acid residues in TMs
3, 5, 6, and 7 predicted by molecular modeling to be involved in ligand recognition were
targeted for replacement with alanine and, in some cases, by other amino acids. Mutated
receptors were expressed in COS-7 cells with an epitope tag that permitted confirmation of
expression in the plasma membrane. A functional assay (i.e., agonist-promoted inositol
phosphate accumulation) was used as a measure of receptor activity. We have attempted to
supplement these results by using the radioligand [35S]α-thio-2′-deoxy-ATP, as reported by
Barnard et al. (30). However, untransfected cells displayed high levels of binding that was
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comparable to COS-7 cells transfected with wild-type P2Y1 receptors but no comparable
activation of phospholipase C by 2-MeSATP (data not shown). Similar conclusions were
reached by Schachter et al. (31) concerning the unsuitability of [35S]α-thio-2′-deoxy-ATP
as radioligand for P2Y1 receptors. Because we already demonstrated the limitations of the
binding of another radioligand, [35S]β-thio-ADP binding (32), for characterization of P2Y
receptors, no suitable radioligand was available.
The current study clearly demonstrates that particular residues of the human P2Y1 receptor
are involved in ligand binding/receptor activation. The functional assay provides direct
information concerning receptor activation and only indirect information concerning ligand
recognition. However, in consideration of the location of the mutated residues proximal to
the exofacial side, the most likely source of major shifts in agonist potency observed in
mutant receptors is interference with ligand recognition. This region was also predicted by
molecular modeling of P2Y1 receptors to be in proximity to the bound ligand (11–13). Many
of the mutated sites are homologous to ligand recognition sites in the human A2A adenosine
receptor (5) (Fig. 1). In contrast, the predominant regions for effector coupling in GPCRs are
known to be located near the cytosolic side of the receptor (4).
Alanine scanning mutagenesis showed that residues R128, K280, Q307, R310, and S314 are
critical for high potency agonist-induced activation of phospholipase C. For K280A and
Q307A mutant receptors, nearly complete concentration-response curves were measured,
and 2-MeSATP was shown to be a full agonist, although at markedly reduced potency
compared with wild-type receptors. Thus, the ability of these mutant receptors to effect
signal transduction was not eliminated. Furthermore, the rescue of function in the S314T
mutant receptor emphasizes the necessity at this position of a hydroxyl group, which may be
available to hydrogen bond to the ligand. The modeling study places the homologous
residue of the chick P2Y1 receptor in proximity to the 2′-hydroxyl group of the ribose
moiety of bound ATP. Overall, these results suggest that residues on the exofacial side of
TM3, TM6, and TM7 are critical determinants of the ATP binding pocket.
In contrast, there was no change in the potency or maximal effect of 2-MeSATP with the
S317A mutant receptor. Thus, this residue is insensitive in adenine nucleotide binding.
Furthermore, alanine replacement of F131, H132, Y136, F226, or H277 resulted in mutant
receptors that exhibited a 7–18-fold reduction in potency of 2-MeSATP compared with that
observed with the wild-type receptor. These five residues in TM3, TM5, and TM6 thus seem
to subserve a less important modulatory role in ligand binding to the P2Y1 receptor. The
three residues in TM3 in this modulatory category would be aligned along the same face of
the helix as the critical residue R128 but are located further from the exofacial side by
approximately one (F131 and H132) or two (Y136) helical turns.
Because changes in the potency of 2-MeSADP and HT-AMP paralleled the changes in
potency of 2-MeSATP at these mutant receptors, the β- and γ-phosphates of the adenine
nucleotides seem to be less important that the α-phosphate in ligand/P2Y1 receptor
interactions. However, T221A and T222A mutant receptors exhibited much larger
reductions in the potency of 2-MeSATP (89- and 33-fold versus wild-type receptors,
respectively) rather than HT-AMP and 2-MeSADP potency. This result may be indicative of
a greater role of these TM5 residues in γ-phosphate recognition. The remaining residues in
TMs 3, 5, 6, and 7 found to be either essential or modulatory for agonist potency did not
show any striking differences among monophosphate, diphosphate, and triphosphate
agonists. Thus, they would be expected to be associated preferentially with the α-phosphate
and/or adenosine moieties of ATP.
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These findings are largely but not entirely consistent with our P2Y1 receptor molecular
model based on a rhodopsin template (12), which predicted that [numbering translated by
homology from the chick P2Y1 receptor sequence] H132(3.33), Y136(3.37), F226(5.47),
H277(6.52), K280(6.55), and R310(7.39), but not R128(3.29), are in proximity to the
triphosphate moiety of bound ATP. The model further predicted that S314 and S317 are in
proximity to the ribose moiety. However, only mutation of the former residue, which is
located closer to the exofacial side, affects ligand binding. Residues F131 and Q307 were
predicted to be in proximity to the adenine moiety (the latter in potentially hydrogen-
bonding proximity from the exocyclic amine), and indeed mutation of these residues caused
a substantial loss of agonist potency (particularly at Q307).
PPADS and suramin retained potency as antagonists (1, 29) in the H277, K280, Q307A,
R310K, S314T, and S317A mutant receptors. Thus, the noncritical (and possibly
modulatory) residues H277, K280, and Q307A seem to be involved especially in agonist
recognition. The S317A mutation seems to be inconsequential for agonist binding. The
rescued mutants R310K and S314T are functional for both agonists and antagonists,
although the potencies determined precisely for agonist are ~1 (S314T) or several orders of
magnitude (R310K) less than those for wild-type receptors. It is not feasible with the present
experimental paradigms to test the ability of the nonactivatable R310K and S314T mutants
to recognize the antagonists PPADS and suramin.
Structural homology of human P2Y1 receptors to other GPCRs
The essential S314(7.43) corresponds to important hydrogen-bonding residues in other
GPCRs, such as tyrosine in adrenergic and muscarinic acetylcholine receptors, and the
essential H278 in human A2A receptors. Although there are numerous parallels between the
P2Y1 receptors and homologous sites in other GPCRs (4), there are some striking
differences. For example, S317(7.46) corresponds to a critical serine residue in the hamster
β2 receptor (33), yet it apparently has no role in ligand recognition in the human P2Y1
receptor. Residue F131(3.32) corresponds to the essential D residue in biogenic amine
receptors (counterion to ligand). For human P2Y1 receptors, this site is less critical for
ligand recognition than in biogenic amine receptors, because its mutation to A resulted in
only a 6.5-fold loss of 2-MeSATP potency.
These findings can be compared with those of Erb et al. (11) with the human P2Y2 (formerly
called P2U) receptor subtype (Fig. 1), which is activated equipotently by UTP and ATP. The
latter study found that although K289(7.36) is positively charged at physiological pH, it is
not involved in phosphate binding. The homologous residue in the human P2Y1 receptor,
the neutral Q307, was proposed in our modeling study (12) to coordinate to the adenine N6-
amino group. In the current study, Q307 was found to be strongly modulatory for agonist
potency.
In addition, in the mouse P2Y2 receptor (11), three positively charged residues, H262(6.52),
R265(6.55), and R292(7.39), were the most critical. Neutralization of each of these residues
individually by replacement with leucine or isoleucine caused a 100–850-fold decrease in
the potency of ATP and UTP (11, 13). Of these three sites, we found only the homologous
residues K280(6.55) and R310(7.39) in the human P2Y1 receptor to be essential for
activation by low concentrations of agonist. Residue N253(6.55) in the human A2A
adenosine receptor (5), which is homologous to K280, is essential for both agonist and
antagonist binding. The residue H277(6.52), homologous to R265 in the P2Y2 receptor, was
only modulatory in the P2Y1 receptor, leading to a 17-fold loss of potency of 2-MeSATP.
Curiously, this residue is conserved between P2Y and P1 receptors. Mutation of the
conserved H250(6.52) in human A2A receptors resulted in a dramatic loss of both agonist
and antagonist affinity (5).
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There is another charged residue K125(3.26) in the TM region that was not mutated in the
current study. In the P2Y2 receptor, replacement of the homologous residue K107(3.26) by
the uncharged L had no effect on agonist potency.
The current study demonstrates the critical importance of R128(3.29), not predicted by
molecular modeling. The homologous residue was not mutated in the P2Y2 receptor (11).
Chemical modification of the cysteinyl mutants of the D2 dopamine receptor (34) suggests
that the residue equivalent in position, V111C(3.29), is solvent exposed in the binding cleft.
Conclusions
The present site-directed mutagenesis study confirms that many of the residues of TM3,
TM5, TM6, and TM7 predicted in a modeling study of P2Y1 receptors to form the
nucleotide binding pocket (12) are indeed involved in ligand recognition. Thus, it seems that
positively charged residues near the exofacial side of both TM3 and TM7 and, to a lesser
extent TM6, are important for recognition of ATP, presumably through interaction with the
negatively charged phosphate moiety. The potency of monophosphate and diphosphate
nucleotide analogues generally varied in parallel to changes for the triphosphate analogue.
Therefore, most structure-function relationships for the receptor were not dependent on
interactions with the β- and γ-phosphates. An exception was the T221T222 sequence in
TM5, for which mutation to A was more detrimental to triphosphate than either
monophosphate or diphosphate potency, suggesting a greater role of this region in γ-
phosphate binding.
Taken together, the results suggest that the adenosine and α-phosphate moieties of ATP
seem to bind to human P2Y1 receptors preferentially in a TM region proximal to the
exofacial side, with the most critical residues located in TM3 and TM7. This study has
revealed differences between P2Y1 and P2Y2 receptors (11), in which positively charged
residues of TM6 and TM7 principally have been proposed to coordinate the phosphate group
of uridine nucleotides. The characterization of structure function differences among P2Y
receptor subtypes will likely aid in the design of highly potent and selective ligands.
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Location of mutations of the human P2Y1 receptor (bold) and alignment of the
transmembrane domains of selected GPCRs for purines/pyrimidines (P2Y and adenosine),
biogenic amines (β-adrenergic, muscarinic cholinergic), and peptides (angiotensin). Sites
mutated in the P2Y2 receptor by Erb et al. (11) and sites in the human A2A adenosine
receptor found to be involved in ligand recognition by Kim et al. (5) are also bold. All are
human sequences except P2Y3 (chicken). Accession numbers are P2Y1, U42030; P2Y2,
U07225; P2Y3, X98283; P2Y4, X91852; P2Y6, X97058; AT1A, M93394; A2A, U40771;
m3ACh, U29589; β2, J02960.
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Stimulation of phospholipase C in COS-7 cells transiently expressing wild-type HA-tagged-
hP2Y1 or mutant hP2Y1 receptors (A, alanine substitutions; B, nonalanine substitutions).
Transfected COS-7 cells were incubated for 30 min at 37° (see Experimental Procedures for
details). Data are presented as absolute accumulations of tritiated inositol phosphates above
basal levels in the absence of 2-MeSATP for a representative experiment. EC50 values
(average of two to four independent experiments, each carried out in duplicate) are given in
Table 2.
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Partial topology of hP2Y1 receptors (TM3–TM7) showing mutation sites in which
replacement by alanine significantly affected the ability of either 2-Me-SATP or HT-AMP
to activate the receptor. Solid circles, >1000-fold loss of potency; striped circles, 100–1000-
fold loss of potency; circles with thick outline, 3–100-fold loss of potency. S317A mutation
(not indicated in figure) had no effect on the agonist potency. The categorization of the
results using HT-AMP as agonist were identical for the cases in which ≥100-fold loss of
potency was observed with 2-MeSATP. Gray circles, residues conserved between P2Y1 and
P2Y2 receptors (R128, R310, and S314 are also conserved).
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Action of antagonists (100 μM) at wild-type receptors (A) and at mutant receptors using 2-
MeSATP (10 nM) as agonist. B, 2-MeSATP was used as agonist at a concentration of 10 nM
(S317A), 100 nM (S314T), 1 μM (H277A and Q307A), or 10 μM (K280A and R310K).
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TABLE 1
ELISA detection of human P2Y1, receptor mutants on the surface of COS-7 cells
Data are presented as means ± standard deviation of eight independent determinations. Table shows
expression level as percentage of Ha-tagged P2Y1, wild-type (100%). Expression level was determined using





R128A 263 ± 4
F131A 150 ± 96
H132A 57.2 ± 4.7
Y136A 50.6 ± 32.5
T221A 87.2 ± 16.9
T222A 123 ± 31
F226A 144 ± 42
H277A 129 ± 6
K280A 148 ± 13
Q307A 151 ± 9
R310A 132 ± 9
R310K 188 ± 40
R310S/S314R 114 ± 5
S314A 125 ± 5
S314T 111 ± 56
S317A 106 ± 23
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TABLE 2
Activation of phospholipase C by mutant human P2Y1 receptors
Data are presented as means ± standard deviation of two to four independent experiments, each performed in
duplicate. All constructs contain the Ha-epitope tag sequence at the amino terminus (5) and a hexa-His tag at






Wild-type 6.75 ± 2.58 1.27 ± 0.01 355 ± 4
R128A 3.29 b b b
F131A 3.32 44.2 ± 15.9 18.2 ± 2.1 5260 ± 2200
H132A 3.33 79.9 ± 29.6 15.9 ± 4.4 2390 ± 600
Y136A 3.37 119 ± 103 12.6 ± 1.8 1720 ± 690
T221A 5.42 604 ± 456 15.9 ± 4.0 1810 ± 280
T222A 5.43 221 ± 58 11.2 ± 0.6 1210 ± 210
F226A 5.47 56.8 ± 7.5 20.7 ± 3.8 1850 ± 800
H277A 6.52 115 ± 28 100 ± 30 4520 ± 640
K280A 6.55 6400 ± 1380 1790 ± 310 203,000 ± 36,000
Q307A 7.36 1400 ± 300 455 ± 140 43,000 ± 600
R310A 7.39 b b b
R310K 7.39 4580 ± 430 418 ± 118 13,400 ± 1700
R310S/S314R 7.39/7.43 b b b
S314A 7.43 b b b
S314T 7.43 60.0 ± 18.0 11.7 ± 1.8 1950 ± 440
S317A 7.46 8.00 ± 1.78 1.58 ± 0.29 611 ± 52
a
Using the sequence identifier as defined in footnote 3 (4).
b
All agonists at the highest concentrations caused only a small increase or no change in inositol phosphates.
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